| Treatment of relapsed/refractory acute myeloid leukemia P Bose, P Vachhani, JE Cortes Current treatment options in oncology 18, 1-30, 2017 | 279 | 2017 |
| NCCN guidelines insights: acute myeloid leukemia, version 2.2021: featured updates to the NCCN guidelines DA Pollyea, D Bixby, A Perl, VR Bhatt, JK Altman, FR Appelbaum, ... Journal of the National Comprehensive Cancer Network 19 (1), 16-27, 2021 | 264 | 2021 |
| Obesity and low vision as a result of excessive Internet use and television viewing A Bener, HS Al-Mahdi, AI Ali, M Al-Nufal, PJ Vachhani, I Tewfik International journal of food sciences and nutrition 62 (1), 60-62, 2011 | 104 | 2011 |
| Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology AT Gerds, J Gotlib, H Ali, P Bose, A Dunbar, A Elshoury, TI George, ... Journal of the National Comprehensive Cancer Network 20 (9), 1033-1062, 2022 | 97* | 2022 |
| Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study YG Najjar, K Navrazhina, F Ding, R Bhatia, K Tsai, K Abbate, B Durden, ... Journal for immunotherapy of cancer 8 (1), 2020 | 92 | 2020 |
| Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy CN Harrison, JS Garcia, TCP Somervaille, JM Foran, S Verstovsek, ... Journal of Clinical Oncology 40 (15), 1671-1680, 2022 | 89 | 2022 |
| Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature N Agrawal, A Khunger, P Vachhani, TA Colvin, A Hattoum, E Spangenthal, ... Case Reports in Oncology 12 (1), 260-276, 2019 | 79 | 2019 |
| Do excessive internet use, television viewing and poor lifestyle habits affect low vision in school children? A Bener, HS Al-Mahdi, PJ Vachhani, M Al-Nufal, AI Ali Journal of child health care 14 (4), 375-385, 2010 | 78 | 2010 |
| Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33/CD3 BiTE®(bispecific T-cell engager) in patients with relapsed … M Subklewe, A Stein, RB Walter, R Bhatia, AH Wei, D Ritchie, V Bücklein, ... Blood 134, 833, 2019 | 75 | 2019 |
| Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia ML Sorror, BE Storer, AT Fathi, A Brunner, AT Gerds, MA Sekeres, ... Blood, 2021 | 61* | 2021 |
| Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology DA Pollyea, JK Altman, R Assi, D Bixby, AT Fathi, JM Foran, I Gojo, ... Journal of the National Comprehensive Cancer Network 21 (5), 503-513, 2023 | 56 | 2023 |
| Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML HM Murdock, HT Kim, N Denlinger, P Vachhani, B Hambley, BS Manning, ... Blood, The Journal of the American Society of Hematology 139 (24), 3546-3557, 2022 | 54 | 2022 |
| VEGF Inhibitors in Renal Cell Carcinoma P Vachhani, S George Clinical Advances in Hematology and Oncology, 2016 | 44 | 2016 |
| Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis I Puzanov, P Subramanian, YV Yatsynovich, DM Jacobs, MR Chilbert, ... Journal for ImmunoTherapy of Cancer 9 (6), 2021 | 41 | 2021 |
| Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML P Vachhani, P Bose, M Rahmani, S Grant Physiological Genomics 46 (13), 448-456, 2014 | 38 | 2014 |
| Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021, NCCN clinical practice guidelines in oncology AT Gerds, J Gotlib, P Bose, MW Deininger, A Dunbar, A Elshoury, ... Journal of the National Comprehensive Cancer Network 18 (9), 1248-1269, 2020 | 32 | 2020 |
| Avapritinib versus placebo in indolent systemic mastocytosis J Gotlib, M Castells, HO Elberink, F Siebenhaar, K Hartmann, ... NEJM evidence 2 (6), EVIDoa2200339, 2023 | 30 | 2023 |
| KRT-232, A first-in-class, murine double minute 2 inhibitor, for myelofibrosis relapsed or refractory to janus-associated kinase inhibitor treatment H Al-Ali, RG Delgado, A Lange, A Pluta, DP McLornan, P Vachhani, ... Hemasphere 4, 215, 2020 | 27 | 2020 |
| North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need N Pemmaraju, H Kantarjian, K Sweet, E Wang, J Senapati, NR Wilson, ... Blood 141 (6), 567-578, 2023 | 26 | 2023 |
| Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience P Vachhani, R Al Yacoub, A Miller, F Zhang, TL Cronin, EP Ontiveros, ... Leukemia research 75, 29-35, 2018 | 26 | 2018 |
